Navid Malik, of The Life Sciences Division talks to Proactive Investors on his investment thesis on ImmuPharma and its late stage drug asset, Lupuzor™ as it gears up to start Phase III trials in Lupus patients in H2 2021 – 18 February 2021
18th February 2021 - 11:06 am